Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purinostat Mesylate + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT06484829Phase 2Recruiting
- Sponsor
- Zenitar
- Start
- Mar 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of purinostat in multiple myeloma (MM), sponsored by Zenitar. Started Mar 2024; status: recruiting.
02
Drugs
purinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06484829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484829.